Client & Alumni News
Tuberculosis has been all but eradicated in the United States, yet is a massive killer worldwide, especially in developing countries. “The goal of TB Biosciences is to develop an accurate, easy-to-use, affordable, rapid point-of-care test to detect active tuberculosis and replace the unreliable sputum smear,” said Sam Niedbala, Ph.D., CEO and co-founder of TB Biosciences, Inc. TB Biosciences secured $1.5 million in Series A financing, including a Ben Franklin investment.
Read more.
